2022 BO42452 – A Phase Ib, Randomized, Placebo-Controlled Study Evaluating The Safety, Pharmacokinetics, Pharmacodynamics, And Efficacy Of Crovalimab For The Management Of Acute Uncomplicated Vaso Occlusive Episodes (VOE) In Patients With Sickle Cell Disease (SCD)
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros.
Previous PostJuma, Bella. "Factors Affecting Haematological Parameters Before and After Introduction of Dolutegravir in Hiv-infected Children at Getrudes Childrens Hospital Comprehensive Care Clinic." PhD diss., University of Nairobi, 2023.
Next Post2022 BO42451 – A Randomized Double-Blind Phase IIa Study Evaluating The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Crovalimab As Adjunct Treatment In Prevention Of Vaso-Occlusive Episodes (Voe) In Sickle Cell Disease (SCD)
